Ryan Cohlhepp Sells 18,750 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 18,750 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total transaction of $524,625.00. Following the sale, the chief operating officer directly owned 181,641 shares of the company’s stock, valued at approximately $5,082,315.18. This represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The shares were sold at an average price of $29.00, for a total value of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.29, for a total transaction of $253,625.00.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $23.63 on Friday. The company’s fifty day moving average is $26.06 and its two-hundred day moving average is $21.79. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.62 and a beta of -0.75. Bicara Therapeutics Inc. has a 52-week low of $10.30 and a 52-week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, meeting the consensus estimate of ($0.82). As a group, sell-side analysts expect that Bicara Therapeutics Inc. will post -3.5 earnings per share for the current fiscal year.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Management said enrollment for the pivotal study of ficerafusp alfa remains on track for 2026. Progress toward this milestone could provide an important catalyst for the clinical-stage biotechnology company. Bicara Therapeutics cancer study remains on track
• Positive Sentiment: Analysts raised several price targets following the quarterly results. BTIG increased its target from $28 to $39 and retained a Buy rating, while Morgan Stanley raised its target to $39 with an Overweight rating. The reported consensus view remains Moderately Buy-rated, with an average target near $32.73. Analysts raise Bicara forecasts
• Neutral Sentiment: Bicara reported a second-quarter loss of $0.82 per share, matching the consensus estimate. The result did not provide a major earnings surprise, leaving clinical execution and upcoming trial milestones as the primary valuation drivers. Bicara Q2 2026 earnings call transcript
• Neutral Sentiment: Wells Fargo raised its price target from $16 to $23 but maintained an Equal Weight rating, highlighting disagreement among analysts about the stock’s risk-reward profile. A reported leadership shake-up also introduces some execution uncertainty as Bicara advances its development programs. Bicara leadership and milestone timeline
• Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep sold a combined 41,250 shares for approximately $1.15 million. The sales were made under pre-arranged Rule 10b5-1 plans, and the executives retained substantial holdings, but the cluster of insider sales can still pressure sentiment.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently bought and sold shares of the business. Deutsche Bank AG raised its position in Bicara Therapeutics by 0.9% in the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after purchasing an additional 1,171 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Mariner LLC increased its stake in shares of Bicara Therapeutics by 3.0% in the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after buying an additional 1,902 shares in the last quarter. Invesco Ltd. increased its stake in shares of Bicara Therapeutics by 13.2% in the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after buying an additional 1,962 shares in the last quarter. Finally, Quantinno Capital Management LP raised its holdings in shares of Bicara Therapeutics by 16.1% in the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after buying an additional 2,447 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Mizuho upped their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday. Wedbush boosted their price target on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Wednesday. Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Guggenheim initiated coverage on shares of Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 target price on the stock. Finally, Wells Fargo & Company upped their target price on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.73.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.